A comment on time-to-event analysis for headache relief [3]

Cephalalgia

Volumn 20, Issue 4, 2000, Pages 255-256

  Tfelt Hansen, P ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; HEADACHE; HUMAN; LETTER; TREATMENT OUTCOME;

ANALGESICS; HEADACHE; HUMANS; INDOLES; OXAZOLIDINONES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS; TRIAZOLES; TRYPTAMINES;

EID: 0034455203     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2000.00052.x     Document Type: Letter

References (9)

1. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology
2. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
3. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
4. Comparison of rizatriptan 10 mg vs. naratriptan in migraine
5. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine
6. 5-HTIB/ID receptor agonists, in the acute treatment of migraine
7. Triptans in migraine: A comparative review of their pharmacology, pharmacokinetics and efficacy
8. Rizatriptan (MAXALT®) for the acute treatment of migraine and migraine recurrence
9. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?